Evidence map›Paper›PMID 37207857›Full record

ArticleInternational journal of pharmaceutics2023

Formulation and processing of solid self-emulsifying drug delivery systems (HME S-SEDDS): A single-step manufacturing process via hot-melt extrusion technology through response surface methodology.

Venkata Raman Kallakunta, Narendar Dudhipala, Dinesh Nyavanandi, Sandeep Sarabu, Karthik Yadav Janga, Srinivas Ajjarapu, Suresh Bandari, Michael A Repka

Open access · greenAbstract read
In one paragraph

Article in International journal of pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Venkata Raman KallakuntaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Narendar DudhipalaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Dinesh NyavanandiDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Sandeep SarabuDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Karthik Yadav JangaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Srinivas AjjarapuDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Suresh BandariDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA.
Michael A RepkaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi 38677, USA; Pii Center for Pharmaceutical Technology, University of Mississippi 38677, USA. Electronic address: marepka@olemiss.edu.
University of Mississippi · US

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI WILLETT, KRISTINE L · 2018 to 2022
$5.3M
NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

The objective of the current study is the formulation development and manufacturing of solid self-emulsifying drug delivery systems (HME S-SEDDS) via a single-step continuous hot-melt extrusion (HME) process. For this study, poorly soluble fenofibrate was selected as a model drug. From the results of pre-formulation studies, Compritol® HD5 ATO, Gelucire® 48/16, and Capmul® GMO-50 were selected as oil, surfactant and co-surfactant respectively for manufacturing of HME S-SEDDS. Neusilin® US2 was selected as a solid carrier. The design of experiments (response surface methodology) was employed to prepare formulations via a continuous HME process. The formulations were evaluated for emulsifying properties, crystallinity, stability, flow properties and drug release characteristics. The prepared HME S-SEDDS showed excellent flow properties, and the resultant emulsions were stable. The globule size of the optimized formulation was 269.6 nm. The DSC and XRD studies revealed the amorphous nature of the formulation and FTIR studies showed no significant interaction between fenofibrate and excipients. The drug release studies showed significant (p < 0.05) improvement in solubility compared to the pure drug (DE

Indexed as

FenofibrateDrug CompoundingDrug Delivery SystemsDrug LiberationEmulsionsExcipientsHot Melt Extrusion TechnologySolubilitySurface-Active AgentsEmulsionsExcipientsFenofibrateSurface-Active AgentsContinuous manufacturingHot-melt extrusionInterfacial tensionSolid self-emulsifying drug delivery systemsSolubility enhancement

Identifiers

PMID37207857
PMCPMC10429704
OpenAlexW4376868902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.